9,366 RSUs granted to Acrivon (ACRV) director for RA Capital funds

Rhea-AI Filing Summary

RA CAPITAL MANAGEMENT, L.P. reported acquisition or exercise transactions in this Form 4 filing.

Acrivon Therapeutics, Inc. reported a compensation-related equity award involving entities affiliated with RA Capital. Director Derek DiRocco received a grant of 9,366 restricted stock units (RSUs), each representing one share of common stock at a price of $0.00 per share. The RSUs vest in full on March 18, 2027, if he continues serving as a director through that date. Under his arrangement with RA Capital Management, L.P. as investment manager, Dr. DiRocco holds these RSUs for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P. and must deliver any settled shares to the adviser to offset advisory fees. As of this filing, 426,302 shares of common stock are held indirectly by the Fund and 11,803,094 shares are held indirectly by Nexus Fund II. The reporting persons and related parties disclaim beneficial ownership of the RSUs and underlying common stock except to the extent of any pecuniary interest.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund II, L.P., Kolchinsky Peter, Shah Rajeev M.

Role null | null | null | null | null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	9,366	$0.00	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 9,366 shares (Indirect, See footnotes)

Footnotes (1)

1. Represents the grant of a restricted stock unit ("RSU") award to Derek DiRocco. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on March 18, 2027, subject to Dr. DiRocco's continuous service as a director through such vesting date. Under Dr. DiRocco's arrangement with the Adviser, Dr. DiRocco holds the RSUs for the benefit of the Fund and the Nexus Fund II. Dr. DiRocco is obligated to turn over to the Adviser any stock received upon settlement of the RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the RSUs and underlying common stock. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. Held directly by the Fund. Held directly by Nexus Fund II.

Key Figures

RSU grant size: 9,366 RSUs Grant price per share: $0.00 per share RSU vesting date: March 18, 2027 +2 more

5 metrics

RSU grant size 9,366 RSUs Equity award to director Derek DiRocco

Grant price per share $0.00 per share RSU award exercise/settlement cost

RSU vesting date March 18, 2027 Full vesting contingent on continued board service

Fund indirect holdings 426,302 shares Common stock held indirectly by RA Capital Healthcare Fund

Nexus Fund II holdings 11,803,094 shares Common stock held indirectly by RA Capital Nexus Fund II

Key Terms

restricted stock unit ("RSU"), pecuniary interest, investment manager, beneficial ownership, +1 more

5 terms

restricted stock unit ("RSU") financial

"Represents the grant of a restricted stock unit ("RSU") award to Derek DiRocco."

pecuniary interest financial

"disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."

investment manager financial

"RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P."

beneficial ownership financial

"disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

advisory fees financial

"stock received upon settlement of the RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser."

Advisory fees are payments made to financial advisors or investment managers for guidance, portfolio management, or other services, typically charged as a fixed amount or a percentage of assets under management. They matter because they lower an investor’s net returns—like paying a mechanic to tune a car, you expect better performance, so investors weigh whether the cost is justified by higher returns, better risk control, or convenience.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RA CAPITAL MANAGEMENT, L.P.

(Last) (First) (Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/18/2026		A		9,366(1)	A	$0	9,366	I	See footnotes(2)(3)
Common Stock								11,803,094	I	See footnotes(3)(4)
Common Stock								426,302	I	See footnotes(3)(5)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

RA CAPITAL MANAGEMENT, L.P.

(Last) (First) (Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

RA Capital Healthcare Fund LP

(Last) (First) (Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

RA Capital Nexus Fund II, L.P.

(Last) (First) (Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Kolchinsky Peter

(Last) (First) (Middle)

C/O RA CAPITAL MANAGEMENT, L.P.

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Shah Rajeev M.

(Last) (First) (Middle)

C/O RA CAPITAL MANAGEMENT, L.P.

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Represents the grant of a restricted stock unit ("RSU") award to Derek DiRocco. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on March 18, 2027, subject to Dr. DiRocco's continuous service as a director through such vesting date.

2. Under Dr. DiRocco's arrangement with the Adviser, Dr. DiRocco holds the RSUs for the benefit of the Fund and the Nexus Fund II. Dr. DiRocco is obligated to turn over to the Adviser any stock received upon settlement of the RSUs, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the RSUs and underlying common stock.

3. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

4. Held directly by the Fund.

5. Held directly by Nexus Fund II.

Remarks:

Dr. Derek DiRocco, a Partner of the Adviser, serves on the Issuer's board of directors.

	/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.	05/20/2026
	/s/ Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC, the General Partner of RA Capital Healthcare Fund, L.P.	05/20/2026
	/s/ Peter Kolchinsky, Manager of RA Capital Nexus Fund II GP, LLC, the General Partner of RA Capital Nexus Fund II, L.P.	05/20/2026
	/s/ Peter Kolchinsky, individually	05/20/2026
	/s/ Rajeev Shah, individually	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Acrivon Therapeutics (ACRV) report in this Form 4?

Acrivon reported a grant of 9,366 restricted stock units to director Derek DiRocco. Each RSU equals one common share and was granted at $0.00 per share as equity compensation, subject to future vesting conditions tied to continued board service.

When do the 9,366 RSUs granted in the ACRV Form 4 vest?

The 9,366 RSUs vest in full on March 18, 2027, if Derek DiRocco continues serving as a director. Vesting means the RSUs convert into common shares, which are then delivered under his arrangement with RA Capital’s investment adviser for fee offset.

Who ultimately benefits from the Acrivon RSU grant reported for Derek DiRocco?

Although granted to Derek DiRocco, the RSUs are held for the benefit of RA Capital Healthcare Fund and RA Capital Nexus Fund II. Shares received upon settlement must be turned over to RA Capital Management, offsetting advisory fees owed by those funds.

How many Acrivon Therapeutics shares are indirectly held by RA Capital funds?

The filing shows 426,302 shares of Acrivon common stock held indirectly by RA Capital Healthcare Fund and 11,803,094 shares held indirectly by RA Capital Nexus Fund II. These holdings are managed by RA Capital Management as investment manager for the two funds.

Do the reporting persons claim beneficial ownership of the ACRV RSUs and shares?

The reporting persons, including RA Capital Management and its principals, disclaim beneficial ownership of the RSUs and underlying common stock, except to the extent of their respective pecuniary interest. This limits how their economic stake is characterized under securities ownership rules.

What is the transaction code used for the Acrivon RSU grant, and what does it mean?

The RSU grant uses transaction code “A,” indicating a grant, award, or other acquisition rather than an open-market purchase. It reflects equity compensation awarded at no cash cost per share, not a discretionary share purchase on the public market.